Emergen Research’s latest market research report, titled Global Pulmonary Drug Delivery Systems Market, provides estimated market size and shares, latest industry trends, global market growth rates, key drivers and opportunities, constraints, product segmentation, and major market players. Cost structure, market size, competitive landscape, product portfolio and specifications, and company profiles.
This report is a fair prototype of the Pulmonary Drug Delivery Systems-industry containing an in-depth study of the global Pulmonary Drug Delivery Systems market. This report serves as a valuable source of data and information related to this industry. It covers various industry aspects with a particular focus on market scope and application areas. The report identifies the fundamental business strategies adopted by industry experts and offers an insightful study on the value chains and distribution channels of the global market. The report authors have also analyzed current industry trends, growth potential, current overview, and market limitations.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4009
The Pulmonary Drug Delivery Systems market is expected to grow from an estimated USD 54.2 billion in 2024 to USD 85.5 billion in 2033, at a CAGR of 5.20%.
The Pulmonary Drug Delivery Systems market is expected to grow from an estimated USD 54.2 billion in 2024 to USD 85.5 billion in 2033, at a CAGR of 5.20%. The Pulmonary Drug Delivery Systems market increase is attributed to the growing incidence of long-term respiratory conditions such cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). The need for these systems has increased as a result of the notable rise in the prevalence and rate of respiratory illnesses, which has led to an increase in the number of patients.
Furthermore, a major contributor to the market’s growth is the favorable support from the government. Initiatives like the U.S. National Asthma Control Initiative (NACI), which emphasizes improved access to inhalation medications and educational campaigns, raise the need for innovative pulmonary drug delivery systems. Similarly, the European Respiratory Society (ERS) collaborates with lawmakers to boost the funding for research and development of respiratory care technologies.
Technological advancements are also driving the expansion, with a focus on smart inhalers with sensors for adherence tracking and real-time monitoring. For instance, Propeller Health, a provider of digital respiratory health solutions, partnered with physicians to integrate smart inhalers into treatment plans in an effort to enhance patient outcomes. Smart inhalers like the Digihaler and Ellipta, created by companies like Teva Pharmaceuticals and GlaxoSmithKline, improve treatment adherence by exchanging data with healthcare practitioners and monitoring in real-time.
Trikafta, a revolutionary treatment for cystic fibrosis from Vertex Pharmaceuticals, is an example of an inhalation system used to address the genetic causes of illnesses. These developments keep broadening the market’s reach.
Additionally, governments around the world are supporting the sector through beneficial policies. The U.S. Food and Drug Administration (FDA) has expedited the clearance of generic inhalation medications as part of its Drug Competition Action Plan, increasing their affordability and accessibility. In the meantime large number of patients in countries like China and India are pushing for the indigenous production of pulmonary drug delivery devices. Growth is also being driven by ageing populations, urbanization, and growing exposure to environmental contaminants. The market for pulmonary drug delivery systems is expected to expand steadily over the next several years because of government support, continuous technological advancements, and the development of healthcare systems in underdeveloped countries.
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Pulmonary Drug Delivery Systems market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Pulmonary Drug Delivery Systems market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Pulmonary Drug Delivery Systems market.
Market Segmentation:
The report bifurcates the Pulmonary Drug Delivery Systems market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
Market competition in the pulmonary drug delivery systems industry is characterized by the presence of global and regional players such as AstraZeneca, Aerogen, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Koninklijke Philips N.V. 3M company, Janssen (Johnson & Johnson), Briggs Healthcare, Clement Clarke International, and others . The global Pulmonary Drug Delivery Systems market is relatively fragmented, with a high level of competition. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market.
Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective solutions.
In Sept 2022, RIGImmune acquired Subintro to access cutting-edge topical delivery techniques. Through the agreement, the biotech will be better positioned to explore new RNA treatments and vaccine adjuvants for local mucosal administration.
Some of the key companies in the global Pulmonary Drug Delivery Systems market include:
- AstraZeneca
- Aerogen
- Boehringer Ingelheim GmbH
- GlaxoSmithKline plc.
- Novartis AG
- Koninklijke Philips N.V.
- 3M company
- Janssen (Johnson & Johnson)
- Briggs Healthcare
- Clement Clarke International
Target Audience of the Global Pulmonary Drug Delivery Systems Market Report:
- Key Market Players
- Investors
- Venture capitalists
- Small- and medium-sized and large enterprises
- Third-party knowledge providers
- Value-Added Resellers (VARs)
- Global market producers, distributors, traders, and suppliers
- Research organizations, consulting companies, and various alliances interested in this sector
- Government bodies, independent regulatory authorities, and policymakers
By Product Outlook (Revenue, USD Billion; 2020-2033)Â
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
By Application Outlook (Revenue, USD Billion; 2020-2033)Â
- Cystic Fibrosis
- Asthma
- Allergic Rhinitis
- COPD
- Other Applications
By End User Outlook (Revenue, USD Billion; 2020-2033)Â
- Hospitals
- Diagnostic Centers
- Other End Users
By Regional Outlook (Revenue, USD Billion; 2020-2033)Â
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/pulmonary-drug-delivery-systems-market
Competitive Terrain:
The global Pulmonary Drug Delivery Systems industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
Growing Utilization of Smart Inhalers
The market for pulmonary drug delivery systems is expanding due in large part to the growing use of smart inhalers. Smart inhalers integrated sensors for customized treatment plans for acute respiratory diseases such as asthma and COPD. For example, Propeller Health has developed smart inhaler devices that can measure inhaler usage and provide personalized insights by interacting with smartphone apps.
 Studies show that patients who use these devices report better illness management, which leads to fewer hospitalizations and improved drug adherence of up to 60%. Another element propelling the market’s growth is collaborations between technology and pharmaceutical businesses. For instance, Adherium and AstraZeneca have teamed up to integrate sensor technology into their inhaler range. Novartis has also utilized Qualcomm’s digital health platform to enhance its respiratory care products.
Government programs that promote digital health also impact the use of smart inhalers. The FDA encourages linked medical device development and approval through its Digital Health Innovation Action Plan. The pulmonary drug delivery systems market is expected to be impacted by the use of smart inhalers, rising consumer awareness, and the need for individualized healthcare.
Key reasons to buy the Global Pulmonary Drug Delivery Systems Market report:
- The latest report comprehensively studies the global Pulmonary Drug Delivery Systems market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.
- The report offers an insightful analysis of the regional outlook of the market.
- It offers a detailed account of the end-use applications of the products & services offered by this industry.
- The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4009
Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com